Clinical Trials Browser

OTHER_GOV × Melanoma × Clear all

NCT07349940 2026-03-27

MEL

Phase NA Recruiting

Melanoma, Nevus, Skin Neoplasms

NCT07349303 2026-01-21

NEOPRIME

Phase 2 Recruiting

Melanoma

NCT07256184 2025-12-15

MEL-CARE

Melanoma

NCT04812470 2025-09-22

HAITILS

Phase 1 Completed

Uveal Melanoma, Melanoma

NCT07183852 2025-09-19

GoTIL-01

Phase 1 Not yet recruiting

Uveal Melanoma, Melanoma

NCT05304546 2025-07-22

MK3475-C01

Phase 2 Completed

Melanoma, Neoplasms

NCT05900102 2025-04-04

Head and Neck Melanoma; Access to Staging and Surgical Treatment

86,000 enrolled

Melanoma

NCT06363591 2025-03-05

WoW

Phase NA Recruiting

Death, Melanoma, Neoplasm Metastasis, Recurrence

NCT05172232 2025-02-05

AI-DSMM

231 enrolled 6 charts

Melanoma

NCT06788665 2025-01-23

AI-DSII

Not yet recruiting

Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Skin Diseases, Skin Neoplasms, Nevi and Melanomas

NCT05212103 2024-12-04

CANSI

Enrolling by invitation

DermatologicOther hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Leukemia, Myeloid, Acute

NCT06670300 2024-11-01

Clinical Observation on the Safety and Efficacy of Cardonilmab in the Treatment of Second-line and Above Advanced Melanoma and Advanced Renal Cancer

Phase 2 Not yet recruiting

DermatologicGenitourinary

Kidney Neoplasms, Melanoma

NCT04924413 2024-07-03

L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

Phase 2 Terminated

Melanoma

NCT03685890 2024-04-25

NivoILP

Phase 1/2 Recruiting

Melanoma

NCT04460053 2024-04-24

ILP-NfL

Phase NA Completed

Melanoma

NCT01785316 2024-01-26

SCANDIUM

Phase 3 Completed

Melanoma, Uveal Neoplasms

NCT03073304 2024-01-26

ILP-Prime

Phase NA Completed

DermatologicSarcoma

Melanoma, Sarcoma

NCT03879395 2024-01-26

SurgMelMet

Abdominal Neoplasms, Melanoma

NCT04242329 2024-01-26

SUMMIST

Phase 2 Withdrawn

Melanoma

NCT05990634 2023-08-14

LifeChamps Feasibility Study

Phase NA Unknown

Melanoma, Neoplasms

NCT05928962 2023-07-10

An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas

Phase 1 Unknown

Melanoma

NCT05903937 2023-06-15

HAITILS-PHP

Phase 1 Not yet recruiting

Uveal Melanoma, Melanoma

NCT05664139 2023-02-08

Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma

Phase 2 Unknown

Melanoma

NCT03166397 2023-01-26

Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

Phase 2 Recruiting

Melanoma

NCT04142931 2021-03-24

Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors

Phase 1 Unknown

BreastDermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Triple Negative Breast Neoplasms

NCT04507048 2020-12-02

PAMela

Phase NA Completed

Melanoma

NCT03643289 2020-02-27

PRIMM

Melanoma

NCT03353402 2019-04-03

Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy

Phase 1 Unknown

Melanoma

NCT03383237 2017-12-27

Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma

Phase 2 Unknown

Melanoma

NCT03285230 2017-09-19

E3N

100,000 enrolled

BreastDermatologicGastrointestinalGynecologicHead & Neck

Asthma, Breast Neoplasms, Cardiovascular Diseases, Colonic Neoplasms, Crohn Disease, Depression, Diabetes Mellitus, Endometriosis, Hypertension, Melanoma, Parkinson Disease, Thyroid Neoplasms, Inflammatory Bowel Diseases, Endometrial Neoplasms

NCT00287131 2012-03-29

Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients

Phase 2 Unknown

Melanoma

NCT00111046 2005-11-10

Pain Relief - Tramadol Versus Ibuprofen

Phase 1/2 Unknown

Uveal Melanoma, Eye Neoplasms, Melanoma